Daily Brief United States: Cloudbreak Pharma, Arbutus Biopharma , Amaero, Thunder Bridge Capital Partner, Fdctech, Snowflake , Janus Living, Southport Acquisition, Syra Health , Veri MedTech Holdings and more

• Cloudbreak Pharma (2592 HK), a clinical-stage eye-disease drug developer, was listed on the HKEx on the 3rd July 2025 at HK$10.10/share, and promptly fell 39% on debut.
• The downward trend continued. Shares were suspended by the SFC on the 10th September 2026, with a last trading price of HK$1.19/share, down 88.2% from IPO. 
• The SFC said it has “serious concerns” that Cloudbreak’s 2025 IPO “may have been rigged to create an artificial impression of demand” for its shares.

• Arbutus Biopharma’s $230m tender offer for 20%-23% of shares is priced between $5.00-$5.75/share, expiring September 29.
• The tender is funded by a $178m settlement from Moderna, with additional cash reserves of $93m as of June.
• Arbutus’s value is primarily in lipid nanoparticle patents, with potential $1.3bn contingent payment from Moderna and ongoing litigation with Pfizer/BioNTech.

• Amaero Inc. is a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing and a pioneer in PM-HIP manufacturing.
• The U.S. addressable market is projected to grow to $1,496.1 million by 2030, supported by a $15.3 million backlog and 680 metric tons capacity.
• As of June 30, 2026, total assets were $88,568, with a net loss of $(13,433) and substantial doubt about going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Thunder Bridge Capital Partners IV, Inc. (THCPU US) is a special purpose acquisition corporation that executed a landmark cross-border business combination with Coincheck Group N.V., one of Japan’s premier licensed cryptocurrency exchange and Web3 platforms backed by Monex Group.
• Pro-forma consolidated revenue expanded rapidly from $1,551.86M in FY2024 to $3,186.93M in FY2026 (a 105.4% two-year increase); however, thin gross margins (2.56% in FY2026) and persistent operational cash burn (-$7.66M in FY2026) underscore high operating leverage and severe sensitivity to digital asset trading velocity.
• Following the de-SPAC transition to Nasdaq under Coincheck Group N.V. (CNCK), institutional value realization depends on diversifying revenue away from commoditized retail spot brokerage toward higher-margin staking, institutional custody, and Web3 asset management amidst complex multi-jurisdictional regulatory oversight.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• FDCTech, Inc. is a financial technology company developing software solutions and business services for OTC brokerage and financial services industries, including its Condor Trading Technology.
• FDCTech’s wealth management business had over $770 million in client assets under advice as of June 30, 2026, serving more than 500,000 users.
• The company reported Total Revenue of $32,687,028 and Net Income of $14,578,197 for the six months ended June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Robust Top-Line Re-Acceleration and AI Adoption: Snowflake has re-accelerated product revenue growth to 37% year-over-year, underpinned by a resilient net revenue retention (NRR) rate of 126% and rapid enterprise adoption of its generative AI engine CoCo, which has surpassed 9,100 accounts alongside growing traction for CoWork.
• Substantial Cash Flow Generation Contrasting GAAP Losses: FY2026 annual revenue reached $4,683.95M with operating cash flow and free cash flow expanding to $1,221.94M and $1,120.31M respectively (23.9% FCF margin), although high stock-based compensation and compute infrastructure investments maintained GAAP net losses at -$1,331.62M.
• Multi-Cloud Moat Balanced Against Premium Valuation: Snowflake’s cloud-agnostic architecture, native data-sharing ecosystem, and expanding support for open table formats (Apache Iceberg) provide a durable economic moat, though current market pricing leaves a narrow margin of safety against hyperscaler competition and macro spending rationalization.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Janus has gained roughly 53% from its $20 IPO price and nearly 30% from its $23.50 first trade, remaining within striking distance of its $32.83 high.
• Second-Quarter results showed 45% revenue growth, 40% adjusted FFO-per-share growth and 19.2% same-store adjusted NOI growth.
• The company has aggressively deployed IPO and follow-on capital, completing approximately $1.8 billion of acquisitions through August 3.

• De-SPAC Transformation and Business Model Evolution: Southport Acquisition Corp (PORT US) completed its business combination with Angel Studios, Inc., successfully transitioning from a blank check shell company into a scaled, audience-curated media and digital entertainment enterprise with proprietary theatrical and streaming distribution infrastructure.
• Financial Inflection and Cash Flow Expansion: Following FY2025 revenue of $321.56M generated largely in the post-merger second half, 1H 2026 results demonstrated steady commercial execution with $226.81M in revenue ($115.11M in Q1 2026 and $111.71M in Q2 2026), solid gross margins above 53%, and an inflection to positive operating cash flow ($1.89M in Q1 2026 and $16.94M in Q2 2026).
• Institutional Investment Considerations: The investment thesis balances a highly differentiated community greenlight model (1.5M+ Angel Guild members) and viral Pay-It-Forward ticketing technology against historical GAAP net losses (-$170.48M in FY2025), hit-driven box-office revenue lumpiness, and post-de-SPAC capital structure dilution.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Transition to Operational Profitability: Syra Health recorded $491,221 in net income for the six months ended June 30, 2026, representing its first sustained pivot to profitability. However, despite positive operating cash flow of $643,183, liquidity remains a serious headwind, with management’s independent auditor continuing to flag a going-concern warning.
• Concentration and Procurement Realities: High revenue concentration—with Humana and the Indiana Family and Social Services Administration (FSSA) historically dominating the receivables ledger—presents an existential risk. State-level procurement cycles spanning 12 to 24 months create structural revenue volatility and prolong Days Sales Outstanding (DSO) on government receivables.
• Digital Health Monetization Demystified: While the Syrenity mental health application has potential under the recently announced CMS ACCESS Model partnership with HealthSync, commercial B2B monetization is still in its infancy. True scalability is limited by high-friction government implementation cycles rather than frictionless, high-margin SaaS expansion.

• Severe Revenue Contraction Driven by Pricing Commodore: Veri MedTech’s flagship platform, Veriheal, experienced a severe 34.3% year-over-year revenue decline from $17 million in 2024 to $11 million in 2025. This contraction was driven by its premium pricing model ($199 for new patients, $149 for renewals) in an increasingly commoditized market where direct competitors like NuggMD and Leafwell have anchored pricing at $99.
• The “Infinite Wellness Loop” is a Valuation Narrative, Not an Operational Reality: The company’s strategic expansion into direct-to-consumer wellness via DosePop is heavily constrained by prohibitive customer acquisition costs (CAC). The cross-sell conversion rate of medical cannabis patients from Veriheal to DosePop is under 2%, failing to validate the executive team’s claims of a self-reinforcing, zero-marginal-CAC retention engine.
• NASDAQ Uplisting is an Absolute Going-Concern Survival Trigger: With a working-capital deficit of $2.05 million and a shareholders’ deficit of $2.35 million as of late 2025, Veri MedTech’s upcoming $15 million NASDAQ uplisting (fixed at $4.00 per share as of September 14, 2026) is a critical liquidity event. Failure to execute this transaction within the next quarter will likely lead to technical default and potential insolvency.